Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742221 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
A Phase 1 study, sponsored by Neumedicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01742221 is a Phase 1 study that has completed, run by Neumedicines. The registered enrollment target is 60 participants.
The verdict
NCT01742221, a Phase 1 study, has completed, sponsored by Neumedicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.
Interventions
- DRUG Placebo
- BIOLOGICAL HemaMax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742221
The ClinicalTrials.gov registry entry for NCT01742221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neumedicines, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01742221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01742221 about?
NCT01742221 is a clinical study titled "Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure". This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.
What is the current status of trial NCT01742221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-08. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01742221?
The interventions under investigation include: Placebo (DRUG), HemaMax (BIOLOGICAL).
Who is sponsoring clinical trial NCT01742221?
This trial is sponsored by Neumedicines, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.